CEO Stephen Griffin was paid $2,033,370 in fiscal year 2025, ↓ down 23.2% from fiscal year 2024, the 6th percentile of its disclosed peer group (SEC filing 0001140361-26-017488 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$4,887,318 Cheryl Blanchard total, FY2025 Executive Chair; Former President and Chief Executive Officer — highest-paid officer; CEO Stephen Griffin: $2,033,370 | 6th CEO (Stephen Griffin) pay percentile vs peers | 44:1 CEO-to-median pay ratio | 88.32% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ANIK's next annual pay disclosure, estimated April 28, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Cheryl Blanchard | $750,397 | $638,000 | $3,476,669 | $0 | $0 | $0 | $22,252 | $4,887,318 |
| Executive Chair; Former President and Chief Executive Officer | ||||||||
| Stephen Griffin | 500,000 | 300,000 | 1,215,222 | 0 | 0 | 0 | 18,148 | 2,033,370 |
| President and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer | ||||||||
| David Colleran | 486,424 | 219,000 | 889,624 | 0 | 0 | 0 | 19,157 | 1,614,205 |
| Executive Vice President, General Counsel and Secretary | ||||||||
| Anne Nunes | 157,639 | 0 | 505,922 | 0 | 0 | 0 | 282,310 | 946,571 |
| Former Senior Vice President, Chief Operations Officer | ||||||||
| Ian McLeod | 345,362 | 121,987 | 275,943 | 0 | 0 | 0 | 22,252 | 765,544 |
| Senior Vice President, Chief Accounting Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Cheryl Blanchard | $4,887,318 | $5,103,466 | $4,459,800 | ↓ −216,148 |
| Stephen Griffin | 2,033,370 | 2,646,150 | — | ↓ −612,780 |
| David Colleran | 1,614,205 | 1,668,587 | 1,550,514 | ↓ −54,382 |
| Anne Nunes | 946,571 | 1,131,633 | 1,013,585 | ↓ −185,062 |
| Ian McLeod | 765,544 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Anika Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ANIK reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses ANIK in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ANIK in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Gary P. Fischetti | Independent Director | $212,497 |
| Glenn R. Larsen, Ph.D | Independent Director | $212,497 |
| John B. Henneman, III | Lead Independent Director | $267,497 |
| Joseph H. Capper | Independent Director | $222,497 |
| Sheryl L. Conley | Independent Director | $224,997 |
| Stephen O. Richard | Independent Director | $229,997 |
| Susan L. N. Vogt | Former director (through FY2025) | $229,997 |
| William R. Jellison | Independent Director | $224,997 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Stephen D. Griffin | Director | 2026-04-30 | A | 12,200 | $12 | $149,881 | Common | Form 4 ↗ |
| John B. Henneman, III | Director | 2026-05-01 | A | 5,000 | 15 | 73,320 | Common | Form 4 ↗ |
| Stephen D. Griffin | Director | 2026-06-03 | D | 12,840 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen D. Griffin | Director | 2026-06-03 | D | 3,769 | 14 | 54,311 | Common | Form 4 ↗ |
| Stephen D. Griffin | Director | 2026-06-03 | A | 12,840 | — | — | Common | Form 4 ↗ |
| Joseph H. Capper | Director | 2026-06-18 | A | 10,402 | 0 | 0 | Common | Form 4 ↗ |
| Sheryl L. Conley | Director | 2026-06-18 | A | 10,402 | 0 | 0 | Common | Form 4 ↗ |
| John B. Henneman, III | Director | 2026-06-18 | A | 10,402 | 0 | 0 | Common | Form 4 ↗ |
| Gary P. Fischetti | Director | 2026-06-18 | A | 10,402 | 0 | 0 | Common | Form 4 ↗ |
| Stephen O. Richard | Director | 2026-06-18 | A | 10,402 | 0 | 0 | Common | Form 4 ↗ |
| Gary P. Fischetti | Director | 2026-08-03 | A | 1,000 | 21 | 20,745 | Common | Form 4 ↗ |
| Gary P. Fischetti | Director | 2026-08-04 | A | 1,000 | 20 | 20,315 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Ian McLeod | RSU | 2025-03-14 | — | — | 17,344 | — | $275,943 |
| Anne Nunes | RSU | 2025-03-14 | — | — | 31,799 | — | 505,922 |
| Cheryl Blanchard | RSU | 2025-03-14 | — | — | 218,521 | — | 3,476,669 |
| David Colleran | RSU | 2025-03-14 | — | — | 55,916 | — | 889,624 |
| Stephen Griffin | RSU | 2025-03-14 | — | — | 76,381 | — | 1,215,222 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Ian McLeod | $275,943 | $0 | $0 | 0.0% |
| Anne Nunes | 505,922 | 0 | 0 | 0.0% |
| Cheryl Blanchard | 3,476,669 | 0 | 0 | 0.0% |
| David Colleran | 889,624 | 0 | 0 | 0.0% |
| Stephen Griffin | 1,215,222 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Colleran | RSU | 14,082 | — | $135,328 |
| Stephen Griffin | RSU | 32,175 | — | 309,202 |
| Cheryl Blanchard | RSU | 71,403 | — | 686,183 |
| Cheryl Blanchard | RSU | 60,900 | — | 585,249 |
| Stephen Griffin | RSU | 38,473 | — | 369,726 |
| David Colleran | RSU | 28,165 | — | 270,666 |
| Stephen Griffin | RSU | 19,236 | — | 184,858 |
| Stephen Griffin | RSU | 18,672 | — | 179,438 |
| Ian McLeod | RSU | 11,324 | — | 108,824 |
| Ian McLeod | RSU | 3,484 | — | 33,481 |
| Ian McLeod | RSU | 3,173 | — | 30,493 |
| Ian McLeod | RSU | 2,536 | — | 24,371 |
| David Colleran | RSU | 15,625 | — | 150,156 |
| David Colleran | RSU | 13,669 | — | 131,359 |
| Cheryl Blanchard | Option | 101,644 | 33.4 | — |
| David Colleran | Option | 35,000 | 43.06 | — |
| Ian McLeod | Option | 7,248 | 44.47 | — |
| Cheryl Blanchard | RSU | 73,559 | — | 706,902 |
| Cheryl Blanchard | Option | 139,168 | 33.4 | — |
We have designed our compensation program to: Motivate and reward our executives to achieve or exceed our financial and operating performance objectives; Propel our business forward through a focus on operational excellence and execution of our business strategy; Link each NEO's compensation with specific business objectives; Align each NEO's compensation with the interests of long-term stockholders by tying a significant portion of total compensation opportunity to the value of our stock; Reinforce accountability and cooperation by tying a significant portion of total NEO compensation to overall Company performance; Attract and retain talented leaders who can drive and implement our growth and operational excellence strategies; Reward individual performance and accomplishments; Keep the compensation packages competitive with those of our peers and other companies with whom we compete for highly-skilled top talent
| CEO STI target (% of salary) | 85% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Willis Towers Watson |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-18 | 8,268,676 | 1,093,946 | 31,179 | 88.32% | Passed |
| 2025 | 2025-06-20 | 8,374,076 | 2,529,081 | 41,849 | 76.8% | Passed |
| 2024 | 2024-07-09 | 11,020,273 | 129,717 | 6,748 | 98.84% | Passed |
| 2023 | 2023-06-14 | 11,873,054 | 227,519 | 51,162 | 98.12% | Passed |
| 2022 | 2022-06-08 | 12,145,089 | 286,360 | 54,847 | 97.7% | Passed |
| 2021 | 2021-06-16 | 9,121,886 | 2,705,453 | 21,311 | 77.13% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-18 | 88.32%a |
| 2025 | 2025-06-20 | 76.8%b |
| 2024 | 2024-07-09 | 98.84%c |
a. Approved under the standard stated in the filing — “Abstentions will not count as votes cast and will have no effect on the vote.”.
b. Approved under the standard stated in the filing — “Abstentions will not count as votes cast and will have no effect on the vote.”.
c. Approved under the standard stated in the filing — “Abstentions will not count as votes cast and will have no effect on the vote.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 44 : 1 |
|---|---|
| CEO total compensation | $4,887,318 |
| Median employee compensation | $112,114 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John B. Henneman, IIIIndependent · Lead Independent Director · Governance and Nominating | $117,500 | $149,997 | $0 | $0 | $0 | $267,497 |
| Susan L. N. VogtIndependent · Departed during FY | 80,000 | 149,997 | 0 | 0 | 0 | 229,997 |
| Stephen O. RichardIndependent · Audit (Chair) · Governance and Nominating | 80,000 | 149,997 | 0 | 0 | 0 | 229,997 |
| Sheryl L. ConleyIndependent · Audit · Compensation (Chair) | 75,000 | 149,997 | 0 | 0 | 0 | 224,997 |
| William R. JellisonIndependent · Audit · Not standing for re-election | 75,000 | 149,997 | 0 | 0 | 0 | 224,997 |
| Joseph H. CapperIndependent · Compensation | 72,500 | 149,997 | 0 | 0 | 0 | 222,497 |
| Glenn R. Larsen, Ph.DIndependent · Compensation · Not standing for re-election | 62,500 | 149,997 | 0 | 0 | 0 | 212,497 |
| Gary P. FischettiIndependent · Compensation | 62,500 | 149,997 | 0 | 0 | 0 | 212,497 |
| Cheryl R. Blanchard, Ph.DEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Stephen D. GriffinEmployee director · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $149,997 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 87,500 / 10,000 |
| Stock ownership guideline | 3x annual Board retainer (directors); 3x base salary (CEO); 1x base salary (other NEOs) |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $625,000 |
| Equity awards (grant-date value) | $1,199,976 |
| All other compensation | $0 |
| Total cost of the board | $1,824,976 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Anika Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Anika Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Vericel Corporation | 2025 | Dominick Colangelo | $860,000 | $3,964,630 | $5,456,287 | $860,000 | $11,156,368 |
| 2 | AxoGen, Inc. | 2025 | Michael Dale | 775,865 | 7,342,895 | 0 | 906,133 | 9,047,454 |
| 3 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 4 | MiMedx Group, Inc. | 2025 | Joseph Capper | 768,173 | 4,699,000 | 819,422 | 887,800 | 7,182,208 |
| 5 | Artivion, Inc. | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 6 | Organogenesis Holdings Inc. | 2025 | Gary Gillheeney | 979,105 | 2,833,330 | 1,380,017 | 1,536,575 | 6,811,754 |
| 7 | Akebia Therapeutics, Inc. | 2025 | John Butler | 864,010 | 2,164,338 | 2,024,798 | 580,973 | 5,652,339 |
| 8 | Rigel Pharmaceuticals, Inc. | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 9 | Avid Bioservices, Inc. | 2024 | Nicholas Green | 650,000 | 3,776,336 | 0 | 0 | 4,475,343 |
| 10 | Bioventus Inc. | 2025 | Robert Claypoole | 824,110 | 1,982,530 | 662,949 | 781,256 | 4,299,108 |
| 11 | Vanda Pharmaceuticals, Inc. | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 12 | SurModics, Inc. | 2024 | Gary Maharaj | 647,481 | 940,000 | 1,410,000 | 654,215 | 3,665,496 |
| 13 | Heron Therapeutics, Inc. | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 14 | Karyopharm Therapeutics, Inc. | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 15 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 16 | Anika Therapeutics | 2025 | Stephen Griffin | 500,000 | 1,215,222 | 0 | 0 | 2,033,370 |
| 17 | Collegium Pharmaceutical, Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Anika Therapeutics | 100% | PSU 67 · RSU 33 | No | Willis Towers Watson |
| Akebia Therapeutics, Inc. | 90% | Options 50 · RSU 25 · MSU 25 | No | Pearl Meyer |
| Artivion, Inc. | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| Avid Bioservices, Inc. | 0% | RSU 50 · PSU 50 | No | Anderson Pay Advisors, LLC |
| AxoGen, Inc. | 116.79% | PSU 50 · RSU 50 | No | Aon |
| Bioventus Inc. | not disclosed | RSU 49 · PSU 26 · Options 25 | No | Aon plc |
| Collegium Pharmaceutical, Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Heron Therapeutics, Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Compensia, Inc. |
| Karyopharm Therapeutics, Inc. | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| MiMedx Group, Inc. | 115% | not disclosed | No | Willis Towers Watson |
| Organogenesis Holdings Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Rigel Pharmaceuticals, Inc. | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| SurModics, Inc. | 126.3% | Option 60 · Restricted Shares 40 | not disclosed | Pay Governance LLC |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| Vanda Pharmaceuticals, Inc. | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
| Vericel Corporation | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Cheryl Blanchard | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Summary Compensation Table” · page 64. As printed: 4,887,318. Filing ↗machine: r2 · c22 · span 1039679–1039688 |
| 2 | Section 01, Stephen Griffin | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Summary Compensation Table” · page 64. As printed: 2,033,370. Filing ↗machine: r5 · c22 · span 1052517–1052526 |
| 3 | Section 01, David Colleran | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Summary Compensation Table” · page 64. As printed: 1,614,205. Filing ↗machine: r7 · c22 · span 1060727–1060736 |
| 4 | Section 01, Anne Nunes | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Summary Compensation Table” · page 64. As printed: 946,571. Filing ↗machine: r10 · c22 · span 1073299–1073306 |
| 5 | Section 01, Ian McLeod | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Summary Compensation Table” · page 64. As printed: 765,544. Filing ↗machine: r13 · c22 · span 1085051–1085058 |
| 6 | Section 03, Ian McLeod RSU | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t333 · r6 · c10 · span 1125919–1125925 |
| 7 | Section 03, Anne Nunes RSU | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t333 · r5 · c10 · span 1122528–1122534 |
| 8 | Section 03, Cheryl Blanchard RSU | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t321 · r2 · c13 · span 1037898–1037907 |
| 9 | Section 03, David Colleran RSU | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t333 · r4 · c10 · span 1118940–1118946 |
| 10 | Section 03, Stephen Griffin RSU | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: t333 · r3 · c10 · span 1115490–1115496 |
| 11 | Section 07, pay ratio | DEF 14A | — | 0001140361-26-017488 | Section “CEO Pay Ratio”. As printed: 44 : 1.machine: span 1618885–1618892 |
| 12 | Section 08, John B. Henneman, III | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Director Compensation”. As printed: 267,497. Filing ↗machine: t381 · r5 · c10 · span 1661039–1661218 |
| 13 | Section 08, Susan L. N. Vogt | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Director Compensation”. As printed: 229,997. Filing ↗machine: t381 · r9 · c10 · span 1669235–1669413 |
| 14 | Section 08, Stephen O. Richard | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Director Compensation”. As printed: 229,997. Filing ↗machine: t381 · r8 · c10 · span 1667387–1667573 |
| 15 | Section 08, Sheryl L. Conley | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Director Compensation”. As printed: 224,997. Filing ↗machine: t381 · r3 · c10 · span 1656945–1657124 |
| 16 | Section 08, William R. Jellison | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Director Compensation”. As printed: 224,997. Filing ↗machine: t381 · r6 · c10 · span 1663249–1663435 |
| 17 | Section 08, Joseph H. Capper | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Director Compensation”. As printed: 222,497. Filing ↗machine: t381 · r2 · c10 · span 1655015–1655201 |
| 18 | Section 08, Glenn R. Larsen, Ph.D | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Director Compensation”. As printed: 212,497. Filing ↗machine: t381 · r7 · c10 · span 1665185–1665364 |
| 19 | Section 08, Gary P. Fischetti | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Director Compensation”. As printed: 212,497. Filing ↗machine: t381 · r4 · c10 · span 1659146–1659332 |
| 20 | Section 08, Cheryl R. Blanchard, Ph.D | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 21 | Section 08, Stephen D. Griffin | DEF 14A | 2026-04-28 | 0001140361-26-017488 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 22 | Section 02, Stephen D. Griffin 2026-04-30 | Form 4 | 2026-04-30 | 0001193125-26-197887 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, John B. Henneman, III 2026-05-01 | Form 4 | 2026-05-04 | 0001193125-26-202704 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Stephen D. Griffin 2026-06-03 | Form 4 | 2026-06-05 | 0001193125-26-259520 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Stephen D. Griffin 2026-06-03 | Form 4 | 2026-06-05 | 0001193125-26-259520 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Stephen D. Griffin 2026-06-03 | Form 4 | 2026-06-05 | 0001193125-26-259520 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Joseph H. Capper 2026-06-18 | Form 4 | 2026-06-23 | 0001193125-26-279539 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Sheryl L. Conley 2026-06-18 | Form 4 | 2026-06-23 | 0001193125-26-279535 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, John B. Henneman, III 2026-06-18 | Form 4 | 2026-06-23 | 0001193125-26-279542 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Gary P. Fischetti 2026-06-18 | Form 4 | 2026-06-23 | 0001193125-26-279545 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Stephen O. Richard 2026-06-18 | Form 4 | 2026-06-23 | 0001193125-26-279541 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Gary P. Fischetti 2026-08-03 | Form 4 | 2026-08-05 | 0001193125-26-335269 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Gary P. Fischetti 2026-08-04 | Form 4 | 2026-08-05 | 0001193125-26-335269 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 06, 2026 vote | Form 8-K | 2026-06-23 | 0001171843-26-004253 | Item 5.07 · say-on-pay result. As reported: 88.32% (votes for as printed: 8,268,676). Filing ↗ |
| 35 | Section 06, 2025 vote | Form 8-K | 2025-06-24 | 0001171843-25-004062 | Item 5.07 · say-on-pay result. As reported: 76.8% (votes for as printed: 8,374,076). Filing ↗ |
| 36 | Section 06, 2024 vote | Form 8-K | 2024-07-11 | 0001171843-24-003900 | Item 5.07 · say-on-pay result. As reported: 98.84% (votes for as printed: 11,020,273). Filing ↗ |
| 37 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 38 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 39 | Section 09b board cost (computed) | Computed | — | — | Cash 625,000 + equity 1,199,976 + all other 0 = 1,824,976, summed across the director compensation table rows.machine: formula: Σ = 1,824,976 |
| 40 | Vericel Corporation, Section 10b CEO total | DEF 14A | 2026-03-19 | 0001308179-26-000094 | CEO total compensation as printed in Vericel Corporation's own proxy. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754 |
| 41 | AxoGen, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0000805928-26-000057 | CEO total compensation as printed in AxoGen, Inc.'s own proxy. As printed: 9,047,454. Filing ↗machine: r2 · c45 · span 557309–557318 |
| 42 | Travere Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 43 | MiMedx Group, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001376339-26-000033 | CEO total compensation as printed in MiMedx Group, Inc.'s own proxy. As printed: 7,182,208. Filing ↗machine: t18 · r2 · c29 · span 444167–444176 |
| 44 | Artivion, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001999371-26-007510 | CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882 |
| 45 | Organogenesis Holdings Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197357 | CEO total compensation as printed in Organogenesis Holdings Inc.'s own proxy. As printed: 6,811,754. Filing ↗machine: r2 · c31 · span 316005–316014 |
| 46 | Akebia Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001517022-26-000034 | CEO total compensation as printed in Akebia Therapeutics, Inc.'s own proxy. As printed: 5,652,339. Filing ↗machine: r3 · c39 · span 516847–516856 |
| 47 | Rigel Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001034842-26-000023 | CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. Filing ↗machine: t120 · r3 · c22 · span 886059–886068 |
| 48 | Avid Bioservices, Inc., Section 10b CEO total | DEF 14A | 2024-08-28 | 0001683168-24-006081 | CEO total compensation as printed in Avid Bioservices, Inc.'s own proxy. As printed: 4,475,343. Filing ↗machine: r1 · c8 · span 442595–442604 |
| 49 | Bioventus Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001665988-26-000014 | CEO total compensation as printed in Bioventus Inc.'s own proxy. As printed: 4,299,108. Filing ↗machine: t53 · r2 · c28 · span 430404–430413 |
| 50 | Vanda Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026893 | CEO total compensation as printed in Vanda Pharmaceuticals, Inc.'s own proxy. As printed: 3,851,468. Filing ↗machine: span 563696–563705 |
| 51 | SurModics, Inc., Section 10b CEO total | DEF 14A | 2024-12-19 | 0000950170-24-138240 | CEO total compensation as printed in SurModics, Inc.'s own proxy. As printed: 3,665,496. Filing ↗machine: r3 · c25 · span 1568790–1568799 |
| 52 | Heron Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-196306 | CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. Filing ↗machine: span 728212–728221 |
| 53 | Karyopharm Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001503802-26-000023 | CEO total compensation as printed in Karyopharm Therapeutics, Inc.'s own proxy. As printed: 2,320,902. Filing ↗machine: r2 · c29 · span 1192339–1192348 |
| 54 | MacroGenics, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001125345-26-000021 | CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. Filing ↗machine: r2 · c57 · span 494189–494198 |
| 55 | Anika Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001140361-26-017488 | CEO total compensation as printed in Anika Therapeutics's own proxy. As printed: 2,033,370. Filing ↗machine: r5 · c22 · span 1052517–1052526 |
| 56 | Collegium Pharmaceutical, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 57 | Section 10a, Karyopharm Therapeutics, Inc. reciprocity | DEF 14A | — | 0001503802-26-000023 | Karyopharm Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 58 | Section 10a, Avid Bioservices, Inc. reciprocity | DEF 14A | — | 0001683168-24-006081 | Avid Bioservices, Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 59 | Section 10a, MiMedx Group, Inc. reciprocity | DEF 14A | — | 0001376339-26-000033 | MiMedx Group, Inc. names Anika Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 60 | Section 10a, Akebia Therapeutics, Inc. reciprocity | DEF 14A | — | 0001517022-26-000034 | Akebia Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 61 | Section 10a, Artivion, Inc. reciprocity | DEF 14A | — | 0001999371-26-007510 | Artivion, Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 62 | Section 10a, Collegium Pharmaceutical, Inc. reciprocity | DEF 14A | — | 0001628280-26-024063 | Collegium Pharmaceutical, Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 63 | Section 10a, AxoGen, Inc. reciprocity | DEF 14A | — | 0000805928-26-000057 | AxoGen, Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 64 | Section 10a, Heron Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-196306 | Heron Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 65 | Section 10a, SurModics, Inc. reciprocity | DEF 14A | — | 0000950170-24-138240 | SurModics, Inc. names Anika Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 66 | Section 10a, MacroGenics, Inc. reciprocity | DEF 14A | — | 0001125345-26-000021 | MacroGenics, Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 67 | Section 10a, Organogenesis Holdings Inc. reciprocity | DEF 14A | — | 0001193125-26-197357 | Organogenesis Holdings Inc. names Anika Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 68 | Section 10a, Rigel Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001034842-26-000023 | Rigel Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 69 | Section 10a, Travere Therapeutics, Inc. reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 70 | Section 10a, Vanda Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-026893 | Vanda Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 71 | Section 10a, Vericel Corporation reciprocity | DEF 14A | — | 0001308179-26-000094 | Vericel Corporation's most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
| 72 | Section 10a, Bioventus Inc. reciprocity | DEF 14A | — | 0001665988-26-000014 | Bioventus Inc.'s most recent proxy was read; its disclosed peer group does not include Anika Therapeutics. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.